Tuesday, October 21, 2008

Teva Announces FDA Approval and Commercial Launch of Fentanyl Transdermal System

Oct 20, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil's chronic pain treatment Duragesic(R). Shipment of this product has commenced.

The details can be read here.

No comments: